Management of substance use disorder in schizophrenia patients: Current guidelines

CNS Spectrums

Volumn 12, Issue 10 SUPPL. 17, 2007, Pages 27-32

  Drake, Robert E ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIOR CHANGE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMORBIDITY; HEALTH CARE DELIVERY; HEALTH PROGRAM; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MENTAL HEALTH; MENTAL HEALTH SERVICE; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSOCIAL CARE; REVIEW; SCHIZOPHRENIA; SMOKING CESSATION; SUBSTANCE ABUSE; TREATMENT PLANNING;

EID: 36048955121     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900026316     Document Type: Review

References (33)

1. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res. 1999;35(suppl):S:93-100.
2. Mueser KT, Noordsy DL, Drake RE, Fox L. Integrated Treatment for Dual Disorders: A Guide to Effective Practice. New York, NY: The Guilford Press; 2003.
3. Drake RE, Brunette MF. Complications of severe mental illness related to alcohol and other drug use disorders. In: Galanter M, ed. Recent Developments in Alcoholism. Vol. 14. New York, NY: Plenum Publishing Company; 1998:285-299.
4. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association; 1994.
5. Minkoff K. An integrated treatment model for dual diagnosis of psychosis and addiction. Hosp Community Psychiatr. 1989;40(10):1031-1036.
6. Ridgely MS, Goldman HH, Willenbring M. Barriers to the care of persons with dual diagnoses: Organizational and financing issues. Schizophr Bull. 1990;16(1):123-132.
7. Drake RE, Osher FC, Noordsy DL, Hurlbut SC, Teague GB, Beaudett MS. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull. 1990;16(1):57-67.
8. McHugo GJ, Drake RE, Burton HL, Ackerson TH. A scale for assessing the stage of substance abuse treatment in persons with severe mental illness. J Nerv Ment Dis. 1995;183(12):762-767.
9. Rosenberg SD, Drake RE, Wolford GL, et al. The Dartmouth Assessment of Lifestyle Instrument (DALI): A substance use disorder screen for people with severe mental illness. Am J Psychiatr. 1998;155(2):232-238.
10. Drake RE, Mueser KT, Brunette MF, McHugo GJ. A review of treatments for people with severe mental illness and co-occurring substance use disorder. Psychiatr Rehabil J. 2004;27(4):360-374.
11. Green AI, Noordsy DL, Brunette MF, O'Keefe C. Substance abuse and schizophrenia: Pharmacotherapeutic intervention. J Subst Abuse Treat. In press.
12. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv. 1996;47(8):853-858.
13. Deegan PE, Drake RE. Shared decision making and medication management in the recovery process. Psychiatr Serv. 2006;57(11):1636-1639.
14. Mueser KT, Corrigan PW, Hilton DW, et al. Illness management and recovery: a review of the research. Psychiatr Serv. 2002;53(10):1272- 1284.
15. Rubio G, Martínez I, Ponce G, Jiménez-Arriero MA, López-Muñoz F, Alamo C. Long-acting financial risperidone compared with zuclopenthixolin the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatr. 2006;51(8):531-539.
16. Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54(10):1395-1401.
17. Siris SG, Mason SE, Bermanzohn PC, Shuwall MA, Aseniero MA. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients. Psychopharmacol Bull. 1993;29(1):127-133.
18. Petrakis IL, O'Malley S, Rounsaville B, et al. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl). 2004;172(3):291-297.
19. Petrakis IL, Nich C, Ralevski E. Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophr Bull. 2006;32(4):644-654.
20. Osher FC, Kofoed LL. Treatment of patients with psychiatric and psychopactive substance use disorders. Hosp Community Psychiatr. 1989;40(10):1025-1030.
21. Drake RE, O'Neal E, Wallach MA. A systematic review of research on interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat. In press.
22. Drake RE, Wallach MA, Alverson HS, Mueser KT. Psychosocial aspects of substance abuse by clients with severe mental illness. J Nerv Ment Dis. 2002;190(2):100-106.
23. Drake RE, Wallach MA, McGovern MP. Future directions in preventing relapse to substance abuse among clients with severe mental illness. Psychiatr Serv. 2005;56(10):1297-1302.
24. Alverson H, Alverson M, Drake RE. An ethnographic study of the longitudinal course of substance abuse among people with severe mental illness. Community Ment Health J. 2000;36(6):557-569.
25. McCoy ML, Devitt T, Clay R, et al. Gaining insight: who benefits from residential, integrated treatment for people with dual diagnoses? Psychiatr Rehabil J. 2003;27(2):140-150.
26. McHugo GJ, Bebout RR, Harris M, et al. A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness. Schizophr Bull. 2004;30(4):969-982.
27. Sengupta A, Drake RE, McHugo GJ. The relationship between substance use disorder and vocational functioning among persons with severe mental illness. Psychiatr Rehabil J. 1998;22:41-45.
28. Drake RE, McHugo GJ, Xie H, Fox M, Packard J, Helmstetter B. Ten-year recovery outcomes for clients with co-occurring schizophrenia and substance use disorders. Schizophr Bull. 2006;32(2):464-473.
29. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157(11):1835-1842.
30. Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of buproprion sustained smoking or smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25(3):218-225.
31. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689-1695.
32. Xie H, Drake RE, McHugo G. Are there distinctive trajectory groups in substance abuse remission over 10 years? An application of the group-based modeling approach. Adm Policy Ment Health. 2006;33(6):423-432.
33. McHugo GJ, Drake RE, Teague GB, Xie H. Fidelity to assertive community treatment and client outcomes in the New Hampshire dual disorders study. Psychiatr Serv. 1999;50(6):818-824.